Navigation Links
Heartland Bridge Capital Takes Equity Stake in Biotech Firm HepatoChem
Date:10/13/2011

MAHWAH, N.J., Oct. 13, 2011 /PRNewswire/ -- Heartland Bridge Capital, Inc. (OTCBB:HLBC), a private equity firm focused on developing a portfolio of unique investments in emerging technologies, announced that it has made its initial funding of $100,000 in biotechnology company HepatoChem, Inc., pursuant to a definitive investment agreement to provide up to $400,000 of equity capital.

Headquartered in Cambridge, MA, HepatoChem is a privately held company that offers pharmaceutical and biotech companies a reliable and efficient means of accessing small molecule metabolites in quantities needed in the drug development process.  HepatoChem's innovative technology uses biomimetic catalysts to mimic the metabolic function of the liver.  This unique technology, developed in collaboration with Professor John Groves at Princeton University, enables the production of metabolites more quickly and with greater cost-effectiveness than any other technology currently available.

James F. Groelinger, the CEO of Heartland Bridge Capital, commented: "We are very excited to be an early investor supporting the commercial development of HepatoChem's extraordinarily innovative technology that should significantly advance the process of commercializing new drugs.  This first step in our relationship with HepatoChem could result in additional investment opportunities in important pharmaceutical developments, and we look forward to seeing this relationship grow into a key element in our overall life sciences portfolio."

Marc Bazin, HepatoChem's founder and CEO, said: "We are pleased to be the beneficiary of this agreement with Heartland Bridge Capital. This first round of financing validates the HepatoChem technology platform, which is a crucial step in the drug development process.  This initial investment into our Company should enable the commercialization of our metabolite production technology, and we see this as an important first step in developing a long-term relationship with Heartland Bridge Capital and its team."

HLBC Investor Conference Call

The Company will be conducting an investor conference call tomorrow at 11:00am EDT to discuss this investment, and Heartland Bridge Capital's overall business strategy.

Date: Friday, October 14, 2011
Time: 11:00 a.m. (EDT)
Dial-in Number: (712) 432-0900
Passcode: 316914

It is recommended that participants phone-in 5 to 10 minutes prior to the start of the call.

Following the event, a replay of the conference call will be available by calling (712) 432-0990, and entering pass code 316914.

About HepatoChem, Inc

HepatoChem is a chemistry based technology platform company with a primary focus on metabolite production from bioactive small molecules.  Founded by Marc Bazin, previously with Pfizer, Inc., and Prof. John T. Groves, the Hugh Stott Taylor Chair of Chemistry at Princeton University, HepatoChem is dedicated to developing technologies that help pharmaceutical companies improve the quality of drug development pipelines.  HepatoChem offers a unique and powerful solution to resolve the lack of rapid and efficient metabolite access in drug discovery. www.hepatochem.com

About Heartland Bridge Capital, Inc.

Heartland Bridge Capital, Inc. (OTCBB:HLBC) is a public company that, in addition to managing its own operating entities, participates in emerging companies run by exceptionally talented entrepreneurs and operating executives who are dedicated to creating positive change in our world.  HLBC will function as an owner, product developer, and investor focused primarily on providing equity, acquisition debt, or bridge financing to emerging high-growth companies and entrepreneurs in the areas of clean energy, waste management, life sciences, and digital document services. www.heartlandbridgecapital.com.

To request an investor packet on Heartland Bridge Capital register online at www.wallstreetnewscast.com/request/hlbc.html

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995).  Heartland Bridge Capital, Inc. cautions that statements made in this news release relating to the investment in HepatoChem, and potential investment in and the business direction of the Company, constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management.  Actual results could differ materially from current projections or implied results.  Heartland Bridge Capital, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contact:

Melissa Diaz,
Investor Relations Counsel
South Street Media
Phone: (347) 483-0121
Email: southstmedia@gmail.com


'/>"/>
SOURCE Heartland Bridge Capital, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Express Scripts HealthBridge Pharma & Biotech to Provide Exclusive Specialty Pharmacy Services and Limited Distribution Services for Solesta®
2. Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundations 2011 M. Judah Folkman International Conference in Cambridge, Mass.
3. Medical Care Technologies Inc. Closes $200,000 Bridge Loan Financing for Kids Health Center
4. BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study
5. Clearbridge BioLoc Unveils Innovative Lab-on-Card Analysis Platform for Point-of-Care Testing at Worlds Largest Clinical Lab Conference
6. Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility
7. BridgePoint Medical Announced 510(k) Clearance for an Expanded Indication to Treat Coronary Chronic Total Occlusions
8. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
9. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
10. BridgePoint Medical Names Industry Veteran as Chief Executive Officer
11. BridgePoint Medical Closes $9.1 Million Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Florida , February 9, 2016 ... today announced a collaboration with 10x Genomics to ... (NGS), single-cell biology and bioinformatics. --> ... a collaboration with 10x Genomics to develop and ... biology and bioinformatics. --> QIAGEN N.V. ...
(Date:2/9/2016)... 2016 The new report "Global Diagnostic Ultrasound Devices Market ... group reveals that global diagnostic ultrasound devices market was valued at ... 7,466.3 million by 2019 at a CAGR of 6.8% from 2015 ... market has been analyzed for six geographies of North ... , Latin America , Middle-East ...
(Date:2/9/2016)... This TforG report includes the Surgical Procedures Database with ... in South Korea . To add ... written and numerical analysis on the current trends, size, ... latest reforms of the local Healthcare system are clearly ... The report helps businesses gain a unique insight into ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... February is Heart Awareness Month, and to celebrate ... the month to the American Heart Association, New Mexico chapter. , A Heart Rate ... and Health Quest’s INSiGHT Pulse Wave Profiler utilizes a non-invasive technology to determine a ...
(Date:2/9/2016)... Campbell, California (PRWEB) , ... ... ... of automated print and e-book publishing software, in partnership with Snowfall4pod Digital, ... AVALANCHE – a comprehensive book publishing, content management, global distribution and print-on-demand ...
(Date:2/9/2016)... ... 2016 , ... The Journal of Pain Research has published the ... , As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention ... pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the ...
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER ... ensure lab personnel have a basic understanding of the techniques they use so ... understanding will help them reduce waste and rework to create a leaner overall ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... sealing company , is proud to announce that many of their franchises have ... customer service. The hard surface restoration franchises received customer recognition through positive reviews ...
Breaking Medicine News(10 mins):